Prevention or Surgical Treatment of Gallstones in Patients Undergoing Gastric Bypass Surgery for Obesity
- PMID: 15010023
- DOI: 10.1007/s11938-004-0030-4
Prevention or Surgical Treatment of Gallstones in Patients Undergoing Gastric Bypass Surgery for Obesity
Abstract
It is well known that obesity is a risk for gallstone formation and biliary sludge. Additionally, it has been clearly shown that rapid weight loss following bariatric surgery is a risk factor for cholesterol cholelithiasis. Multiple serious complications from gallstones such as cholecystitis, cholangitis, gallstone pancreatitis, and cholecystenteric fistulae may occur. Thus, it is necessary to employ medical or surgical methods to prevent or treat gallstones in this group. Therapy should be individualized. Although there is a high incidence of gallstones in this group, only a minority of individuals will develop symptomatic disease. When used in patients who are compliant, ursodeoxycholic acid therapy can be effective to prevent gallstone formation during rapid weight loss. The cost effectiveness of routine ursodeoxycholic acid therapy compared with the potential costs of complicated gallstone disease needs to be further investigated. Combined cholecystectomy with Roux-en-Y gastric bypass surgery is a safe and appropriate therapeutic option in those with preoperatively known gallstones, biliary sludge, and prior episodes of cholecystitis. However, routine cholecystectomy at the time of gastric bypass surgery is not warranted for all patients because of the increased time of operation and postoperative hospitalization, as well as all the potential complications after cholecystectomy. The approach of routine cholecystectomy in this setting subjects many patients to an unnecessary procedure because the majority will not develop symptoms or complications of gallstones. Furthermore, cholecystectomy is technically easier to perform after weight loss occurs.
Similar articles
-
Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery: study protocol for a randomized controlled trial (UPGRADE trial).BMC Gastroenterol. 2017 Dec 20;17(1):164. doi: 10.1186/s12876-017-0674-x. BMC Gastroenterol. 2017. PMID: 29262795 Free PMC article. Clinical Trial.
-
Ursodeoxycholic Acid for 6 Months After Bariatric Surgery Is Impacting Gallstone Associated Morbidity in Patients with Preoperative Asymptomatic Gallstones.Obes Surg. 2019 Apr;29(4):1216-1221. doi: 10.1007/s11695-018-03651-0. Obes Surg. 2019. PMID: 30604076
-
Cholelithiasis and cholecystitis.J Long Term Eff Med Implants. 2005;15(3):329-38. doi: 10.1615/jlongtermeffmedimplants.v15.i3.90. J Long Term Eff Med Implants. 2005. PMID: 16022643 Review.
-
Gallbladder management in obesity surgery.Obes Surg. 2002 Apr;12(2):222-9. doi: 10.1381/096089202762552395. Obes Surg. 2002. PMID: 11975217
-
Obesity and the risk and prognosis of gallstone disease and pancreatitis.Best Pract Res Clin Gastroenterol. 2014 Aug;28(4):623-35. doi: 10.1016/j.bpg.2014.07.013. Epub 2014 Jul 22. Best Pract Res Clin Gastroenterol. 2014. PMID: 25194180 Review.
Cited by
-
Concomitant cholecystectomy should be routinely performed with laparoscopic Roux-en-Y gastric bypass.Surg Endosc. 2015 Nov;29(11):3106-11. doi: 10.1007/s00464-014-4033-5. Epub 2014 Dec 17. Surg Endosc. 2015. PMID: 25515986
References
LinkOut - more resources
Full Text Sources
Research Materials